Literature DB >> 29327941

Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets.

Bradley H Rosen1,2, T Idil Apak Evans1, Shashanna R Moll1, Jaimie S Gray1, Bo Liang1, Xingshen Sun1, Yulong Zhang1, Chandler W Jensen-Cody1, Anthony M Swatek3, Weihong Zhou1, Nan He1, Pavana G Rotti1,4, Scott R Tyler1, Nicholas W Keiser1, Preston J Anderson1, Leonard Brooks3, Yalan Li5, R Marshall Pope5, Maheen Rajput6, Eric A Hoffman6, Kai Wang7, J Kirk Harris8, Kalpaj R Parekh3, Katherine N Gibson-Corley9, John F Engelhardt1,2.   

Abstract

RATIONALE: Classical interpretation of cystic fibrosis (CF) lung disease pathogenesis suggests that infection initiates disease progression, leading to an exuberant inflammatory response, excessive mucus, and ultimately bronchiectasis. Although symptomatic antibiotic treatment controls lung infections early in disease, lifelong bacterial residence typically ensues. Processes that control the establishment of persistent bacteria in the CF lung, and the contribution of noninfectious components to disease pathogenesis, are poorly understood.
OBJECTIVES: To evaluate whether continuous antibiotic therapy protects the CF lung from disease using a ferret model that rapidly acquires lethal bacterial lung infections in the absence of antibiotics.
METHODS: CFTR (cystic fibrosis transmembrane conductance regulator)-knockout ferrets were treated with three antibiotics from birth to several years of age and lung disease was followed by quantitative computed tomography, BAL, and histopathology. Lung disease was compared with CFTR-knockout ferrets treated symptomatically with antibiotics.
MEASUREMENTS AND MAIN RESULTS: Bronchiectasis was quantified from computed tomography images. BAL was evaluated for cellular differential and features of inflammatory cellular activation, bacteria, fungi, and quantitative proteomics. Semiquantitative histopathology was compared across experimental groups. We demonstrate that lifelong antibiotics can protect the CF ferret lung from infections for several years. Surprisingly, CF animals still developed hallmarks of structural bronchiectasis, neutrophil-mediated inflammation, and mucus accumulation, despite the lack of infection. Quantitative proteomics of BAL from CF and non-CF pairs demonstrated a mucoinflammatory signature in the CF lung dominated by Muc5B and neutrophil chemoattractants and products.
CONCLUSIONS: These findings implicate mucoinflammatory processes in the CF lung as pathogenic in the absence of clinically apparent bacterial and fungal infections.

Entities:  

Keywords:  airway obstruction; cystic fibrosis; ferret; inflammation; mucus

Mesh:

Substances:

Year:  2018        PMID: 29327941      PMCID: PMC5955060          DOI: 10.1164/rccm.201708-1616OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   30.528


  54 in total

Review 1.  Submucosal glands and airway defense.

Authors:  Jeffrey J Wine; Nam Soo Joo
Journal:  Proc Am Thorac Soc       Date:  2004

Review 2.  Respiratory tract mucin genes and mucin glycoproteins in health and disease.

Authors:  Mary Callaghan Rose; Judith A Voynow
Journal:  Physiol Rev       Date:  2006-01       Impact factor: 37.312

3.  MCP-1/CCR2B-dependent loop upregulates MUC5AC and MUC5B in human airway epithelium.

Authors:  Maria E Monzon; Rosanna Malbrán Forteza; S Marina Casalino-Matsuda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-19       Impact factor: 5.464

4.  Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B.

Authors:  Sara Kirkham; John K Sheehan; David Knight; Paul S Richardson; David J Thornton
Journal:  Biochem J       Date:  2002-02-01       Impact factor: 3.857

5.  MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways.

Authors:  P Sharma; L Dudus; P A Nielsen; H Clausen; J R Yankaskas; M A Hollingsworth; J F Engelhardt
Journal:  Am J Respir Cell Mol Biol       Date:  1998-07       Impact factor: 6.914

6.  Airway Mucin Concentration as a Marker of Chronic Bronchitis.

Authors:  Mehmet Kesimer; Amina A Ford; Agathe Ceppe; Giorgia Radicioni; Rui Cao; C William Davis; Claire M Doerschuk; Neil E Alexis; Wayne H Anderson; Ashley G Henderson; R Graham Barr; Eugene R Bleecker; Stephanie A Christenson; Christopher B Cooper; MeiLan K Han; Nadia N Hansel; Annette T Hastie; Eric A Hoffman; Richard E Kanner; Fernando Martinez; Robert Paine; Prescott G Woodruff; Wanda K O'Neal; Richard C Boucher
Journal:  N Engl J Med       Date:  2017-09-07       Impact factor: 91.245

7.  Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.

Authors:  Stefanie Gehrig; Julia Duerr; Michael Weitnauer; Claudius J Wagner; Simon Y Graeber; Jolanthe Schatterny; Stephanie Hirtz; Abderrazzaq Belaaouaj; Alexander H Dalpke; Carsten Schultz; Marcus A Mall
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

8.  Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung.

Authors:  D A Groneberg; P R Eynott; T Oates; S Lim; R Wu; I Carlstedt; A G Nicholson; K F Chung
Journal:  Respir Med       Date:  2002-02       Impact factor: 3.415

Review 9.  Airway mucus hypersecretion in asthma: an undervalued pathology?

Authors:  Duncan F Rogers
Journal:  Curr Opin Pharmacol       Date:  2004-06       Impact factor: 5.547

10.  Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

Authors:  Peter D Sly; Siobhain Brennan; Catherine Gangell; Nicholas de Klerk; Conor Murray; Lauren Mott; Stephen M Stick; Philip J Robinson; Colin F Robertson; Sarath C Ranganathan
Journal:  Am J Respir Crit Care Med       Date:  2009-04-16       Impact factor: 21.405

View more
  50 in total

1.  Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways.

Authors:  Yan Shin J Liao; Shin Ping Kuan; Maria V Guevara; Emily N Collins; Kalina R Atanasova; Joshua S Dadural; Kevin Vogt; Veronica Schurmann; Laura Bravo; Eda Eken; Mariana Sponchiado; Leah R Reznikov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-03-11       Impact factor: 5.464

2.  Derivation of induced pluripotent stem cells from ferret somatic cells.

Authors:  Jinghui Gao; Sophia Petraki; Xingshen Sun; Leonard A Brooks; Thomas J Lynch; Chih-Lin Hsieh; Reem Elteriefi; Zareeb Lorenzana; Vasu Punj; John F Engelhardt; Kalpaj R Parekh; Amy L Ryan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-19       Impact factor: 5.464

Review 3.  Update in Cystic Fibrosis 2018.

Authors:  Bonnie W Ramsey; Gregory P Downey; Christopher H Goss
Journal:  Am J Respir Crit Care Med       Date:  2019-05-15       Impact factor: 21.405

Review 4.  Past, Present, and Future Research on the Lung Microbiome in Inflammatory Airway Disease.

Authors:  Lindsay J Caverly; Yvonne J Huang; Marc A Sze
Journal:  Chest       Date:  2019-05-30       Impact factor: 9.410

5.  Viral Vectors, Animal Models, and Cellular Targets for Gene Therapy of Cystic Fibrosis Lung Disease.

Authors:  Yinghua Tang; Ziying Yan; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2020-04-15       Impact factor: 5.695

6.  Mucus accumulation in the lungs precedes structural changes and infection in children with cystic fibrosis.

Authors:  Charles R Esther; Marianne S Muhlebach; Camille Ehre; David B Hill; Matthew C Wolfgang; Mehmet Kesimer; Kathryn A Ramsey; Matthew R Markovetz; Ian C Garbarine; M Gregory Forest; Ian Seim; Bryan Zorn; Cameron B Morrison; Martial F Delion; William R Thelin; Diane Villalon; Juan R Sabater; Lidija Turkovic; Sarath Ranganathan; Stephen M Stick; Richard C Boucher
Journal:  Sci Transl Med       Date:  2019-04-03       Impact factor: 17.956

7.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

Review 8.  Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.

Authors:  Giulio Cabrini
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

9.  Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis.

Authors:  Hamed Horati; Hettie M Janssens; Camilla Margaroli; Mieke Veltman; Marta Stolarczyk; Matthew B Kilgore; Jeffrey Chou; Limin Peng; Harm A M W Tiddens; Joshua D Chandler; Rabindra Tirouvanziam; Bob J Scholte
Journal:  J Cyst Fibros       Date:  2020-02-10       Impact factor: 5.482

10.  Elastase Exocytosis by Airway Neutrophils Is Associated with Early Lung Damage in Children with Cystic Fibrosis.

Authors:  Camilla Margaroli; Luke W Garratt; Hamed Horati; A Susanne Dittrich; Timothy Rosenow; Samuel T Montgomery; Dario L Frey; Milton R Brown; Carsten Schultz; Lokesh Guglani; Anthony Kicic; Limin Peng; Bob J Scholte; Marcus A Mall; Hettie M Janssens; Stephen M Stick; Rabindra Tirouvanziam
Journal:  Am J Respir Crit Care Med       Date:  2019-04-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.